Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: Aravinda M. DeSilva
Organization: UNIV OF NORTH CAROLINA CHAPEL HILL
Fiscal Year: 2020
Award: $528,796
Funding agency: National Cancer Institute

Abstract
High-quality recombinant antigens and reliable and accurate SARS-CoV-2 serological assays are urgently
needed for surveillance and for defining the immune mechanisms of viral pathogenesis, viral clearance, and
protection against reinfection. Core B of the UNC SARS-CoV-2 Serological Sciences Center of Excellence will
apply state-of-the-art strategies to establish methods for the production of milligram quantities of homogeneous
recombinant spike protein CoV antigens with versatile tags and site-specific labels and use these antigens to
develop sensitive and reliable singleplex and multiplex Ab detection assays. Core B will interact and support all
the projects driven by the center and collaborators' by providing recombinant antigens and serological assays to
characterize the serum antibody response, elucidate Fc effector functional profiles, and isolate and sequence
antigen-specific immunoglobulin gene repertoire.

Terms: <2019 novel coronavirus><2019-nCoV><Affinity><Antibodies><Antibody Response><Antigen Receptors><Antigens><Antisera><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bioassay><Biologic Assays><Biological Assay><Blood Serum><CoV S protein><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><Containment><Coronaviridae><Coronavirus><Coronavirus glycoprotein S><Coronavirus spike protein><Detection><ELISA><Enzyme-Linked Immunosorbent Assay><Exposure to><Fc Receptor><Goals><Gold><HCoV><Health Facilities><Health care facility><Healthcare Facility><Ig Genes><Immune><Immune Sera><Immunes><Immunoglobulin Genes><Individual><Infection><Label><Length><MERS><MERS coronavirus disease><MERS-CoV disease><Mammalian Cell><Measures><Methods><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><N-terminal><NH2-terminal><North Carolina><Nucleocapsid><Palsy><Paralysed><Pathogenicity><Pattern><Plegia><Production><Property><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><Recombinants><Research><Research Grants><Research Project Grants><Research Projects><Resource Sharing><SARS><SARS Virus><SARS corona virus><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Science><Serologic><Serologic tests><Serological><Serological Tests><Serum><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Site><Sorting - Cell Movement><Specificity><Structure><System><Testing><Vaccines><Viral><Viral Pathogenesis><Virus><Wuhan coronavirus><antibody receptor><base><care facilities><corona virus><coronavirus S protein><coronavirus spike glycoprotein><human CoV><human corona virus><human coronavirus><immune serum><immunogen><milligram><pandemic><pandemic disease><paralysis><paralytic><receptor binding><receptor bound><serology><severe acute respiratory syndrome-CoV><sorting><virus pathogenesis>